2,4,5-Trifluorobenzyl Bromide CAS 157911-56-3 Puritas >98.0% (GC) Ensitrelvir (S-217622) Intermedia COVID-19

Description:

Nomen chemicum: 2,4,5-Trifluorobenzyl Bromide

CAS: 157911-56-3

Puritas: >98.0% (GC)

Aspectus: Hyalina in luce Yellow Serena Liquid

Medium Ensitrelvir (S-217622), COVID-19 .

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Commercial Supple Ensitrelvir (S-217622) Intermedia:
S-Ethylisothiourea Hydrobromide CAS 1071-37-0
2,4,5-Trifluorobenzyl Bromide CAS 157911-56-3
Trimethyloxonium Tetrafluoroborate CAS 420-37-1
6-Chloro-2-methyl-2H indazol-5-amine CAS 1893125-36-4
3-(Chloromethyl) -1-methyl-1H-1,2,4-triazolum hydrochloridum CAS 135206-76-7
1,3,5-Triazine-2,4(1H,3H)-dione, 3-(1,1-dimethylethyl)-6-(ethylthio)- CAS 1360105-53-8

Chemical Properties:

Nomen chemicum	2,4,5-Trifluorobenzyl Bromide
Synonyma	1-(Bromomethyl)-2,4,5-trifluorobenzene
CAS Number	157911-56-3
CATTUS Number	RF-PI1505
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C7H4BrF3
M. Pondus	225.01
Mico punctum	75℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Hyalina in luce Yellow liquida liquida
Puritas / Analysis Methodus	>98.0% (GC)
Humor (KF)	≤0.50%
Gravitas Imprimis (20/20)	1.714~1.719
Index refractivus (N20/D)	1.505~1.509
Totalis immunditias	<2.00%
Infrared Imaginis	Conformat ut Structure
Test Standard	Enterprise Standard
Consuetudinem	Pharmaceutical intermedia

Sarcina & Repono:

sarcina: Utrem, 25kg/ferrum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

FAQ:

Applicatio:

2,4,5-Trifluorobenzyl Bromide (CAS: 157911-56-3) maxime adhibetur in industria pharmaceutica sicut intermedium pharmaceuticum.2,4,5-Trifluorobenzyl Bromide maximus est medius in synthesi Sitagliptin (CAS: 486460-32-6).2,4,5-Trifluorobenzyl Bromide est etiam intermedius magni momenti inter Ensitrelvir (S-217622).Ensitrelvir, medicamentum medicinale pro COVID-19, inhibitor 3CL protease creatus est per investigationem communem inter Universitatem Hokkaido et Shionogi.SARS-CoV-2 enzyma 3CL protease vocatur, quae necessaria est replicationi viri.Ensitrelvir replicationem SARS-CoV-2 supprimit per selective inhibendo 3CL protease.